top of page

UPDATES
&
IN THE PRESS

Office Hallway

ATHERION BIORESEARCH 
A DIFFERENT KIND OF CRO

We have been there. We are drug development professionals who have worked on successful drug development from early preclinical all the way through to approval and commercialization. We have been on the sponsor side as well as the services side. We know what it takes. Let us make a difference for you.

February 1, 2024

Atherion Bioresearch Announces Agreement with NoyMed CRO to Bring Advanced Biometrics Solutions with an International Partner for Clinical Trials

DUBLIN, Ohio—Atherion Bioresearch, Inc. ("Atherion" or the "Company"), a full-service Clinical Research Organization ("CRO") company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with NoyMed CRO ("NoyMed"), an international clinical research organization offering advanced biometrics solutions to biotech, pharma, and medical device firms.

The companies establish a solid partnership through this agreement to offer their services to potential sponsors jointly or individually. Atherion Bioresearch and NoyMed CRO can refer potential clients to each other in order to provide an expanded suite of services.

Atherion offers a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion's founding members are drug development professionals who have successfully worked on the sponsor side to advance drugs and complete trials and have private and public pharmaceutical/biotechnology experience. Atherion's team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement.

For over 10 years, NoyMed CRO has been offering expert biostatistics, clinical data management (CDM), statistical programming, CDISC (Clinical Data Interchange Standards Consortium) conversion, medical writing, and pharmacovigilance solutions in almost all therapeutic areas. NoyMed CRO operates internationally, with offices in the United States (Glendale, CA, Denver, CO) and Armenia (Yerevan, Vanadzor, Gyumri). Through leadership and extensive industry experience, NoyMed CRO has driven 170+ clinical trials to success, focusing on enhancing project quality and minimizing project delivery timelines.

Atherion has selected NoyMed CRO as one of its partners because of its expertise in biometrics, adding an essential set of data-driven tools to Atherion's service offerings. Atherion's strengths in medical imaging, radiopharmaceuticals and radiotherapeutics, and its deep regulatory experience in these and other areas expand NoyMed's arsenal.

Michael Rosol, Ph.D., Chief Executive Officer of Atherion, said, "I am delighted to announce this agreement with NoyMed that will help amplify the reach and accelerate the growth of both of our companies." Dr. Rosol continued, "Atherion has experience in clinical trial operations and strategy, and NoyMed brings deep expertise in biometrics across a wide domain of therapeutic areas. This collaboration will help us further differentiate our organizations from the competition and enable us to bring additional high quality services to sponsors."

January 4, 2024

Atherion Bioresearch Announces Agreement with CISYS LifeSciences to Bring Software as a Service eClinical Solutions to Clinical Trials

DUBLIN, Ohio—Atherion Bioresearch, Inc. (“Atherion” or the “Company”), a full-service Clinical Research Organization (“CRO”) company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with CISYS LifeSciences, Inc. (“CISYS”), a clinical research-oriented Software as a Service (“SaaS”) solutions company dedicated to improving sponsor's clinical research initiatives by applying technology in a common sense driven, cost effective, collaborative, and FDA-compliant manner. Through this agreement, the companies have entered into a partnership to offer their services to potential sponsors either in combination or individually and will refer potential clients to each other in order to offer an expanded suite of services. 


Atherion offers a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion’s founding members are drug development professionals who have worked on the sponsor side to successfully advance drugs and complete trials and who have both private and public pharmaceutical/biotechnology experience. Atherion’s team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement. 


CISYS leadership brings decades of experience in providing clinical research-oriented SaaS solutions, technology consulting, and software development to the pharmaceutical and biotech community.  CISYS’s extensive experience with clinical research-oriented software development, databases, technology platforms, and computer system validation allow it to provide significant insight, recommend best practices, and streamline sponsor’s research processes and operations. CYSIS’s client list encompasses industry leaders to startups. 


The combination of the experience and expertise of these two companies brings together a powerful platform of services to help sponsors with their drug development needs.


Michael Rosol, PhD, Chief Executive Officer of Atherion, said, “I am delighted to announce this agreement with CISYS that will help amplify the reach and accelerate the growth of both of our companies.” Dr. Rosol continued, “Atherion has the experience in clinical trial operations and strategy and CISYS brings to the table deep expertise in clinical research software solutions, including its clinical event adjudication and patient eligibility e-clinical programs. This relationship will help us further differentiate our organizations from the competition and enable us to bring more efficiencies to sponsors.”


Jim Saunders, President/founder of CISYS, said, “It’s a great partnership opportunity for both of our companies to reach new levels in 2024. We figured out quite early in discussions that Michael Rosol and his team at Atherion Bioresearch are aligned with our vision of improving AI innovation, efficiency, and most importantly, quality. We are looking forward to this amazing opportunity of a results-oriented relationship.”

October 31, 2023

Anju Welcomes Atherion Bioresearch as the Newest CRO Partner

Atherion is excited to announce a strategic partnership with Anju Software, a leading provider of adaptable life science solutions for clinical research, medical affairs, and data science. This collaboration represents a milestone in the clinical research industry, uniting to drive advancement, streamline processes, and enhance data integrity. 

Paul Sahargun, SVP of eClinical at Anju, commented, "We look forward to this new partnership with Atherion. Through our combined resources we can redefine the standard for data integrity, operational efficiency, and patient-focused clinical trials." 
 
You can read the full press release here: https://lnkd.in/g7gTUDcY

October 9, 2023

Atherion Bioresearch Announces Agreement with Voxeleron to Bring Advanced Ophthalmic Imaging Analysis and Clinical Trial Management Services to Ophthalmology

DUBLIN, Ohio—Atherion Bioresearch, Inc. (“Atherion” or the “Company”), a full-service Clinical Research Organization (“CRO”) company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with Voxeleron, LLC. (“Voxeleron”), the leader in ophthalmic imaging analysis and ophthalmic clinical trial management solutions. Through this agreement, the companies are able to offer an expanded suite of services to potential sponsors.

Atherion provides a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion’s founding members are drug development professionals who have worked on the sponsor side to successfully advance drugs and complete trials and who have both private and public pharmaceutical/biotechnology experience. Atherion’s team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement.

Voxeleron leadership brings decades of experience in computer vision and image analysis to imaging in ophthalmology, particularly for optical coherence tomography (“OCT”). Orion™, Voxeleron’s ophthalmic image analysis software, enables reading of images and data from the entire spectrum of devices,  allowing readers to attain best-in-class segmentation with proven, AI-enhanced analysis, and reduces read times through automated measurements using intuitive interfaces. Orion’s advanced analysis tools are fully automated and entirely platform independent – truly vendor neutral – and processes data from all major OCT scanners in any of their formats. It also seamlessly interfaces with iNebula™, the company’s complete, cloud-based clinical trial data platform.

The combination of the experience and expertise of these two companies brings together a powerful platform of services to help sponsors with their drug development needs.

Michael Rosol, PhD, Chief Executive Officer of Atherion, said, “I am pleased to announce this agreement with Voxeleron that will help amplify the reach and accelerate the growth of both of our companies.” Dr. Rosol continued, “Atherion has the experience in clinical trial operations and strategy and Voxeleron brings to the table deep expertise in ophthalmic clinical image management and image analysis software. Together our two companies can function as a full-service ophthalmic imaging CRO in addition to our other capabilities in clinical development and imaging software solutions.”

Jonathan Oakley, Chief Scientific Officer of Voxeleron, said, “We are very excited to be working with Atherion.  A clinical trial has so many moving parts, it is almost impossible to be the best at them all.  This partnership leverages our abilities in a very complete and resonant way to give sponsors an exceptionally strong option for managing their trials.”

September 21, 2023

Atherion Bioresearch Expands to Offer Dosimetry Services
with Voximetry As Preferred Provider

DUBLIN, OH — Atherion Bioresearch, a full-service Clinical Research Organization (CRO) company, has selected Voximetry to expand the capabilities they provide to include advanced dosimetry.

  

Atherion offers a wide array of drug development services and is differentiated by its high level of engagement, industry experience, and expanding support services.  Atherion’s experienced team knows there are challenges to outsourcing to CROs and strives to fill the role of trusted partner in the therapeutic pipeline.

Voximetry is a commercial stage medical software and services company with proprietary advanced dosimetry technology and an experienced team dedicated to supporting the clinical use and development of personalized Radiopharmaceutical Therapy (RPT) treatments.   Patient-specific dosimetry can help improve trial design, save time, and reduce the cost of achieving clinical endpoints.  

According to Voximetry CEO, Dr. Sue Wallace, “We are pleased to be selected by Atherion as a trusted partner.    We’re confident in our ability to help with pre-study design and accurate dose assessments, but none of that matters without the innovation of the drug development community.   Atherion’s intimate knowledge of the needs and common pitfalls of the drug development process will help us hone our services to earn and maintain a favored-partner status.”

There are currently over 200 active RPT clinical trials, but personalized dosimetry requires a high level of medical physics expertise that is not readily available.   In this competitive environment, services like that offered by Voximetry can make a difference in the success of a drug development program.

“We selected Voximetry because they have the most accurate dose assessment technology available but have been surprised and delighted by the depth of expertise on their team.  They provide timely, comprehensive, and thoughtful consulting support.  They make it a priority to assure the data are collected, analyzed, and presented in a way we can trust to guide development decisions,” stated Dr. Mike Rosol, Atherion CEO.   “Being able to include Voximetry expertise in the list of comprehensive services we already offer differentiates us to our sponsors. Together, we offer a more innovative, effective, and efficient practice to drug development.”

About Atherion: Atherion was established by a team of drug development professionals dedicated to helping clients efficiently advance their pipelines while avoiding the cost and timeline impact typically associated with the use of contract research organizations.  Atherion offers full-service or bespoke clinical research services tailored from our decades of industry experience that enable clients to develop their technology towards successful commercialization. 

 About Voximetry:  Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company specializing in commercialization of complex algorithms on high-speed Graphics Processing Units (GPUs).    Currently focused on radiation transport science and voxel-level dosimetry, Voximetry is pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.  https://voximetry.com/ 

August 25, 2023

Atherion Bioresearch Announces Agreement with Radiant Sage to Bring Full Suite of Imaging Management Services to Clinical Trials

DUBLIN, Ohio—Atherion Bioresearch, Inc. (“Atherion” or the “Company”), a full-service Clinical Research Organization (“CRO”) company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with Radiant Sage Ventures, LLC. (“Radiant Sage”), a clinical trial imaging management solutions and services CRO dedicated to providing sponsors with the most efficient acquisition, processing, and delivery of imaging information available today. Through this agreement, the companies have entered into a partnership to offer their services to potential sponsors in either combination or individually and will refer potential clients to each other in order to offer an expanded suite of services. 

 

Atherion offers a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion’s founding members are drug development professionals who have worked on the sponsor side to successfully advance drugs and complete trials and who have both private and public pharmaceutical/biotechnology experience. Atherion’s team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement. 

 

Radiant Sage leadership brings decades of experience in clinical image management and analysis software for clinical trials and a thorough understanding of the need for robust clinical trial imaging infrastructure solutions and services for organizations involved in drug discovery and research. The combination of the experience and expertise of these two companies brings together a powerful platform of services to help sponsors with their drug development needs.

 

Michael Rosol, PhD, Chief Executive Officer of Atherion, said, “I am excited to announce this agreement with Radiant Sage that will help amplify the reach and accelerate the growth of both of our companies.” Dr. Rosol continued, “Atherion has the experience in clinical trial operations and strategy and Radiant Sage brings to the table deep expertise in clinical image management and analysis software. Together our two companies can function as a full-service imaging CRO in addition to our other capabilities in clinical development and imaging software solutions.”

 

Venkatesan Thangaraj, Chief Executive Officer of Radiant Sage, said, “We are excited to partner with Atherion to provide sponsors a differentiated offering that provides solid execution commitment and advantage to meet sponsor needs and requirements in this rapidly changing environment.”

About Atherion
Atherion Bioresearch, Inc. is a hybrid Clinical Research Organization (“CRO”) and Drug Development (pharmaceutical) company. Atherion was established by a team of experienced drug development professionals dedicated to helping our partners advance their pipelines. Atherion is staffed by professionals who have been successful on the sponsor side; we know where the gaps are and what the need is. We offer full-service or bespoke clinical research services, enabling clients to develop their technology and grow their pipeline. Whether it be preclinical research from target or drug discovery to clinical research from First in Human to Phase IV, we are passionate about working with our partners to develop innovative medicines that will positively impact people's lives. On the drug development side, we are evaluating technologies for in-licensing to form a pipeline in the theranostic and therapeutic spaces for indications including cancer, where there are large unmet needs. 

About Radiant Sage 
Radiant Sage provides game-changing clinical trial imaging infrastructure solutions and services for organizations involved in drug discovery and research. Specifically designed for clinical trials, the company’s solutions, RadClinica™, Core-Lab-in-a-Box™ and RadVista™ Viewer are extremely flexible and offer self-contained customization tools enabling rapid trial start and increased overall efficiency of the collection, distribution, processing, and analysis of clinical trial imaging data. The use of Radiant Sage’s technologies provide sponsors with the ability to retain control of their clinical trials by leveraging these cost-effective image management solutions designed with real-time transparency in reporting at every level of the entire process. These secure and validated tools also offer increased image/data integrity over current corelab processes and meet all necessary compliance requirements. Founded in 2008, Radiant Sage is headquartered in Boston, Mass. For more information, please visit www.radiantsage.com.
 

July 18, 2023

Atherion Bioresearch Announces Collaborative Agreement with PolygenRx to Bring Expanded Suite of Services to Clinical Trials

Today Atherion Bioresearch, Inc. ("Atherion") announced that it has entered into a collaborative agreement with PolygenRx, https://www.polygenrx.com/, the pharmagenic enrichment company dedicated to genetically informed drug discovery and precision medicine for complex disorders, to offer an expanded suite of services to our clients! Using PolygenRx's proprietary platform, it is possible to reduce the cost of clinical trials by reducing the number of participants needed to drive regulatory approval. PolygenRx achieves these outcomes by genetically enriching treatment groups with responsive participants. This agreement expands upon Atherion's growing ability to offer leading edge capabilities to enable more efficient advancement of your clinical pipeline.

July 14, 2023

Atherion Bioresearch Announces Collaborative Agreement with Monitored Theraputics, Inc. to Bring Expanded Suite of Services to Clinical Trials

Today Atherion Bioresearch, Inc. ("Atherion") announced that it has entered into a collaborative agreement with Monitored Therapeutics, Inc., https://monitoredrx.com/, the remote patient monitoring company and provider of the leading lab-quality respiratory platform for monitoring patients at home or in clinic for healthcare and clinical trials, to offer an expanded suite of services to our clients! At Atherion we provide a high level of engagement and experience along with partnerships like this to offer leading edge capabilities to more efficiently advance your clinical pipeline. 

May 17, 2023

Atherion Bioresearch Announces Collaborative Agreement with SPRS for Trials to Bring Expanded Suite of Services to Clinical Trials

DUBLIN, Ohio—Atherion Bioresearch, Inc. (“Atherion” or the “Company”), a full-service Clinical Research Organization (“CRO”) company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with Strategic Patient Recruitment Solutions for Trials, LLC. (“SPRS”), a patient-recruitment focused CRO dedicated to ensuring patient engagement and enrollment in sponsored clinical trials. Through this agreement, the companies have entered into a non-exclusive partnership to offer their services to potential sponsors in either combination or individually and will refer potential clients to each other in order to offer an expanded suite of services to sponsors.

 

Atherion offers a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion’s founding members are drug development professionals who have worked on the sponsor side to successfully advance drugs and complete trials and who have both private and public pharmaceutical/biotechnology experience. Atherion’s team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement.

 

SPRS leadership brings decades of experience in clinical trials and CRO business development and a thorough understanding of the need for a high level of engagement to scale up and maintain patient involvement and recruitment into trials involving all disease indications. The combination of the experience and expertise of these two companies brings together a powerful platform of services to help sponsors with their drug development needs.

 

Michael Rosol, PhD, Chief Executive Officer of Atherion, said, “I am excited to announce this collaborative agreement with SPRS that will help amplify the reach and accelerate the growth of both of our companies.” Dr. Rosol continued, “Atherion has the experience in clinical trial operations and strategy and SPRS brings to the table deep expertise in patient-centric recruitment solutions. Together our two companies close the significant gaps sponsors currently face when running trials, whether outsourced or run internally, engagement and efficiency.”

 

Maria Frane, President of SPRS, said, “It’s really nice to collaborate with a CRO whose leadership have come from drug development sponsors.  They can truly put themselves in the shoes of our clients and  strive to provide the level of excellence they expect and deserve.  Together, we’ll break the mold of the traditional CRO and provide an innovative, practical and efficient approach to drug development and clinical trials.”

 

About Atherion

Atherion Bioresearch, Inc. is a hybrid Clinical Research Organization (“CRO”) and Drug Development (pharmaceutical) company. Atherion was established by a team of experienced drug development professionals dedicated to helping our partners advance their pipelines. Atherion is staffed by professionals who have been successful on the sponsor side; we know where the gaps are and what the need is. We offer full-service or bespoke clinical research services, enabling clients to develop their technology and grow their pipeline. Whether it be preclinical research from target or drug discovery to clinical research from First in Human to Phase IV, we are passionate about working with our partners to develop innovative medicines that will positively impact people's lives. On the drug development side, we are evaluating technologies for in-licensing to form a pipeline in the theranostic and therapeutic spaces for indications including cancer, where there are large unmet needs. For more information, please visit www.atherion-bioresearch.com.

 

About SPRS

Strategic Patient Recruitment Solutions (“SPRS”), LLC., is a clinical research services company focused on the critical need for patient recruitment into clinical trials. Studies have shown that 38.7% of terminated trials are due to slow enrollment, and 86% of trials fail to meet their enrollment timelines. Clinical trial sites are overburdened and understaffed. SPRS strives to understand the challenges each site faces and provides the support needed to recruit and enroll patients. Patients are often not in close proximity to a trial site or are not ambulatory. SPRS provides virtual and travel solutions to patients who can't get to the trial site. SPRS can also provide resources for research naive point of care sites. Through site support, decentralized solutions, public relations, marketing, and patient advocacy, SPRS plans for success and executes methods to effectively and efficiently enroll clinical trials. For more information, please visit www.sprsfortrials.com.

 

Forward-Looking Statements

This press release contains forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: uncertainty of future revenue and profitability; our ability to successfully complete research and development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; advances in technologies and development of new competitive products; the impact of the current coronavirus pandemic; and other risk factors. 

Potential investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

bottom of page